 |
 |
Dear Celia,
Thank you for your email. The information wasn’t provided in the abstract, just that in my experience the tests are not being used routinely. The survey questions
were designed to help me establish to what extent organic bioaccessibility methods are being used in the UK so I could report the results as part of my presentation. So far I have only had one ‘yes’ response, but this was in relation to inorganics – very interesting
answers though.
It would still be very useful to here from the group about their experience with organic bioaccessibility in line with the questions below or indeed other thoughts
about why these tests are not being used widely e.g. lack on information, lack of confidence in results, minimal impact on decision making?
Best wishes,
Darren
From: cecilia.macleod [mailto:[log in to unmask]]
Sent: 18 September 2015 11:29
To: Beriro, Darren J.; [log in to unmask]
Subject: RE: Organic Human Bioaccessibility Survey
Wasn’t this information provided in your abstract?
Dr
Cecilia
Macleod
FRSC FGS CCHEM CSCI
Director
WYG
100 St John Street, London, EC1M 4EH
Tel: +44
207 250 7752
Fax: +44
207 250 7501
Mob: +44
7881 914 370
www.wyg.com
••••••••••••••••••••••••••••••••••••••••••••••••••••••
|
WYG Environment Planning Transport Limited. Registered in England number: 3050297. Registered Office: Arndale Court, Otley Road, Headingley, Leeds, West Yorkshire
LS6 2UJ VAT No: 431-0326-08
|
From: Contaminated Land Management Discussion List [mailto:[log in to unmask]]
On Behalf Of Beriro, Darren J.
Sent: 11 September 2015 14:11
To: [log in to unmask]
Subject: Organic Human Bioaccessibility Survey
Dear Group,
I am speaking at the gasworks MGP 2015 symposium in Ghent later this year (http://mgpsymposium.com/) and in support of
this I would like to conduct a survey to assess the application of organic bioaccessibility testing to human health risk assessment in the UK. If you have any involvement in this aspect of risk-based land management I would be very grateful for your participation.
Please could you respond to me directly via [log in to unmask] and I will collate the responses and summarise the results to the group. I have adopted the word 'use' in the questions but this refers to implementation,
commissioning, reviewing and/or using the test / test results.
The survey questions are as follows:
1.
Which method(s) of bioaccessibility testing have you used?
2.
Which pathway did you apply the test to?
3.
At how many sites have you used the test?
4.
What context were the test results used e.g. derivation of site specific risk assessment criteria prior to remediation, derivation remediation targets?
5.
Which substances were tested e.g. BaP, PCB-118?
6.
Would you be willing to share the results of the test with me for collation i.e. number of samples, averaging area, % bioaccessible fraction for each
sample (anonymity of sample location assumed)?
7.
What difference did the results make to the decision making process e.g. increased site specific assessment criteria and therefore reduced remediation?
8.
What other lines-of-evidence did you use to support the test results?
When responding please can you state your name, affiliation, position and whether you would mind being contacted to follow up on any of your answers. If you
are responding as a lab then I understand that some of the questions might not apply. Thank you very much in advance for your assistance.
Best wishes,
Darren
-------------------------------------
-------------------------------------
Medical Geology
Environmental Modelling
British Geological Survey
Keyworth
Nottingham
NG12 5GG
Direct dial: 0115 936 3479
Swtichboard: 0115 936 3100
-------------------------------------
-------------------------------------
________________________________
This message (and any attachments) is for the recipient only. NERC is subject to the Freedom of Information Act 2000 and the contents of this email and any reply you make may be disclosed by NERC unless it is exempt from release under the
Act. Any material supplied to NERC may be stored in an electronic records management system.
________________________________
This message contains confidential information and is intended only for the recipient. If you are not the recipient you should not disseminate, distribute or copy this e-mail.
Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed,
arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. If verification is required please request a hard-copy
version.
